Solano Pharmaceuticals

Solano Pharmaceuticals was a pre-clinical stage biopharmaceutical company focused on the development of novel therapeutics for neurodegenerative diseases. The company's primary asset was XJB-5-131, a synthetic, mitochondrial-targeted nitroxide antioxidant designed to mitigate oxidative damage and inhibit ferroptosis. Solano targeted indications such as Huntington's disease, Alzheimer's disease, and Parkinson's disease, where mitochondrial dysfunction and lipid peroxidation play critical roles. The company was founded by researchers including Dr. Peter Wipf and operated out of Berkeley, California, but has since become inactive.